Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
University of California, Davis
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
University of Texas Southwestern Medical Center
Karyopharm Therapeutics Inc
Weill Medical College of Cornell University
Georgetown University
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
GSO Global Clinical Research BV
St. Jude Children's Research Hospital
University of California, San Francisco
Ohio State University Comprehensive Cancer Center